Skip to main content

Advertisement

SpringerLink
Log in

Rheumatoid arthritis

Moving towards IMPROVED drug-free remission

  • News & Views
  • Published:

From Nature Reviews Rheumatology

View current issue Sign up to alerts

The newly published 5-year outcomes of the IMPROVED trial demonstrate the feasibility of achieving long-term drug-free remission in early rheumatoid arthritis (RA). These findings raise the bar and support the use of a remission induction and maintenance approach, particularly in patients presenting with early joint inflammation consistent with early RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kuijper, T. M., Lamers-Karnebeek, F. B., Jacobs, J. W., Hazes, J. M. & Luime, J. J. Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. J. Rheumatol. 42, 2012–2022 (2015).

    Article  CAS  Google Scholar 

  2. Akdemir, G. et al. Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study. Ann. Rheum. Dis. 77, 111–118 (2017).

    Article  Google Scholar 

  3. Heimans, L. et al. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann. Rheum. Dis. 73, 1356–1361 (2014).

    Article  CAS  Google Scholar 

  4. Heimans, L. et al. Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study). Arthritis Res. Ther. 18, 23 (2016).

    Article  Google Scholar 

  5. Akdemir, G. et al. Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study. RMD Open 2, e000172 (2016).

    Article  Google Scholar 

  6. Emery, P. et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann. Rheum. Dis. 74, 19–26 (2015).

    Article  CAS  Google Scholar 

  7. Emery, P. et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N. Engl. J. Med. 371, 1781–1792 (2014).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

V.P.B. has received grants from the National Institutes of Health, Patient-Centered Outcomes Research Institute and the Canadian Institutes of Health Research.

Author information

Authors and Affiliations

  1. Weill Cornell Medical College, New York, NY, USA

    Vivian P. Bykerk

  2. The Inflammatory Arthritis Center, Hospital for Special Surgery, New York, NY, USA

    Vivian P. Bykerk

Authors
  1. Vivian P. Bykerk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vivian P. Bykerk.

Ethics declarations

Competing interests

V.P.B. declares she has acted as an adviser for Amgen, BMS, Pfizer, Sanofi-Genzyme and UCB, and that her institute has received research funding from Amgen, BMS and UCB.

Supplementary information

Supplementary information S1 (box)

The IMPROVED trial 1 year and 2 year outcomes (PDF 86 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bykerk, V. Moving towards IMPROVED drug-free remission. Nat Rev Rheumatol 14, 191–192 (2018). https://doi.org/10.1038/nrrheum.2018.49

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2018.49

  • Springer Nature Limited

This article is cited by

Search

Navigation